Expert Rev Anti Infect Ther. 2006 Dec;4(6):939-45.

Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent.

Source

Virginia Commonwealth University, Department of Internal Medicine, Richmond, VA, USA. pfulco@mcvh-vcu.edu

Abstract

Ramoplanin, a novel antibiotic with activity against aerobic and anaerobic gram-positive bacteria, acts to prevent cell wall peptidoglycan formation by binding to a key intermediate moiety, lipid II. It has been fast-tracked by the US FDA for the prevention of enterococcal infections and the treatment of Clostridium difficile. The minimum inhibitory concentration(90s) have been < or = 1.0 microg/ml against gram-positive organisms examined. In carriers of vancomycin-resistant enterococci, a double-blind, placebo-controlled Phase II trial of two doses of ramoplanin versus placebo showed proof of concept. A second Phase II trial also demonstrated the equivalence of ramoplanin compared with vancomycin for the treatment of C. difficile colitis. The clinical value and place in therapy of ramoplanin is dependent upon the results of Phase III trials addressing its utility in suppressing carriage of target organisms in the gastrointestinal tract or in the nares.

PMID:: 17181409; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Antibiotics - MedlinePlus Health Information

Supplemental Content

Related citations

Review Ramoplanin: a lipoglycodepsipeptide antibiotic. [Ann Pharmacother. 2005]
Review Ramoplanin: a lipoglycodepsipeptide antibiotic.
Farver DK, Hedge DD, Lee SC. Ann Pharmacother. 2005 May; 39(5):863-8. Epub 2005 Mar 22.
In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. [Antimicrob Agents Chemother. 2...]
In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.
Peláez T, Alcalá L, Alonso R, Martín-López A, García-Arias V, Marín M, Bouza E. Antimicrob Agents Chemother. 2005 Mar; 49(3):1157-9.
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. [Antimicrob Agents Chemother. 2...]
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ. Antimicrob Agents Chemother. 2003 Jul; 47(7):2334-8.
Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. [J Antimicrob Chemother. 2005]
Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.
Freeman J, Baines SD, Jabes D, Wilcox MH. J Antimicrob Chemother. 2005 Oct; 56(4):717-25. Epub 2005 Sep 5.
Review Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. [J Antimicrob Chemother. 2003]
Review Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients.
Montecalvo MA. J Antimicrob Chemother. 2003 Jun; 51 Suppl 3:iii31-5.

See reviews... See all...

Cited by 1 PubMed Central article

Enduracidin analogues with altered halogenation patterns produced by genetically engineered strains of Streptomyces fungicidicus. [J Nat Prod. 2010]
Enduracidin analogues with altered halogenation patterns produced by genetically engineered strains of Streptomyces fungicidicus.
Yin X, Chen Y, Zhang L, Wang Y, Zabriskie TM. J Nat Prod. 2010 Apr 23; 73(4):583-9.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent.
Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent.
Expert Rev Anti Infect Ther. 2006 Dec ;4(6):939-45.

PubMed
The mechanism of action of ramoplanin and enduracidin.
The mechanism of action of ramoplanin and enduracidin.
Mol Biosyst. 2006 Jan ;2(1):69-76. Epub 2005 Nov 29 .

PubMed
A comparison of available and investigational antibiotics for complicated skin i...
A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
J Drugs Dermatol. 2007 Jan ;6(1):97-103.

PubMed
Ramoplanin: a lipoglycodepsipeptide antibiotic.
Ramoplanin: a lipoglycodepsipeptide antibiotic.
Ann Pharmacother. 2005 May ;39(5):863-8. Epub 2005 Mar 22 .

PubMed
UV Light B-Mediated Inhibition of Skin Catalase Activity Promotes Gr-1(+)CD11b(+...
UV Light B-Mediated Inhibition of Skin Catalase Activity Promotes Gr-1(+)CD11b(+) Myeloid Cell Expansion.
J Invest Dermatol. 2012 Mar ;132(3 Pt 1):695-702. doi: 10.1038/jid.2011.329. Epub 2011 Oct 27 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: